00008626686/30TRUE2024Q3FALSEfalse7,415,329FALSE000-201270.0010.00135,000,00035,000,0007,415,3297,415,3297,415,3297,415,3290.0010.0012,000,0002,000,0002,000,0002,000,000xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesesmc:votexbrli:pure00008626682023-07-012024-03-3100008626682024-05-1300008626682024-03-3100008626682023-06-300000862668us-gaap:SecuredDebtMember2024-03-310000862668us-gaap:SecuredDebtMember2023-06-300000862668us-gaap:ProductMember2024-01-012024-03-310000862668us-gaap:ProductMember2023-01-012023-03-310000862668us-gaap:ProductMember2023-07-012024-03-310000862668us-gaap:ProductMember2022-07-012023-03-310000862668us-gaap:ServiceMember2024-01-012024-03-310000862668us-gaap:ServiceMember2023-01-012023-03-310000862668us-gaap:ServiceMember2023-07-012024-03-310000862668us-gaap:ServiceMember2022-07-012023-03-3100008626682024-01-012024-03-3100008626682023-01-012023-03-3100008626682022-07-012023-03-310000862668us-gaap:PreferredStockMember2023-06-300000862668us-gaap:CommonStockMember2023-06-300000862668us-gaap:AdditionalPaidInCapitalMember2023-06-300000862668us-gaap:RetainedEarningsMember2023-06-300000862668us-gaap:PreferredStockMember2023-07-012023-09-300000862668us-gaap:CommonStockMember2023-07-012023-09-300000862668us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000862668us-gaap:RetainedEarningsMember2023-07-012023-09-3000008626682023-07-012023-09-300000862668us-gaap:PreferredStockMember2023-09-300000862668us-gaap:CommonStockMember2023-09-300000862668us-gaap:AdditionalPaidInCapitalMember2023-09-300000862668us-gaap:RetainedEarningsMember2023-09-3000008626682023-09-300000862668us-gaap:PreferredStockMember2023-10-012023-12-310000862668us-gaap:CommonStockMember2023-10-012023-12-310000862668us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-310000862668us-gaap:RetainedEarningsMember2023-10-012023-12-3100008626682023-10-012023-12-310000862668us-gaap:PreferredStockMember2023-12-310000862668us-gaap:CommonStockMember2023-12-310000862668us-gaap:AdditionalPaidInCapitalMember2023-12-310000862668us-gaap:RetainedEarningsMember2023-12-3100008626682023-12-310000862668us-gaap:PreferredStockMember2024-01-012024-03-310000862668us-gaap:CommonStockMember2024-01-012024-03-310000862668us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000862668us-gaap:RetainedEarningsMember2024-01-012024-03-310000862668us-gaap:PreferredStockMember2024-03-310000862668us-gaap:CommonStockMember2024-03-310000862668us-gaap:AdditionalPaidInCapitalMember2024-03-310000862668us-gaap:RetainedEarningsMember2024-03-310000862668us-gaap:PreferredStockMember2022-06-300000862668us-gaap:CommonStockMember2022-06-300000862668us-gaap:AdditionalPaidInCapitalMember2022-06-300000862668us-gaap:RetainedEarningsMember2022-06-3000008626682022-06-300000862668us-gaap:PreferredStockMember2022-07-012022-09-300000862668us-gaap:CommonStockMember2022-07-012022-09-300000862668us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000862668us-gaap:RetainedEarningsMember2022-07-012022-09-3000008626682022-07-012022-09-300000862668us-gaap:PreferredStockMember2022-09-300000862668us-gaap:CommonStockMember2022-09-300000862668us-gaap:AdditionalPaidInCapitalMember2022-09-300000862668us-gaap:RetainedEarningsMember2022-09-3000008626682022-09-300000862668us-gaap:PreferredStockMember2022-10-012022-12-310000862668us-gaap:CommonStockMember2022-10-012022-12-310000862668us-gaap:AdditionalPaidInCapitalMember2022-10-012022-12-310000862668us-gaap:RetainedEarningsMember2022-10-012022-12-3100008626682022-10-012022-12-310000862668us-gaap:PreferredStockMember2022-12-310000862668us-gaap:CommonStockMember2022-12-310000862668us-gaap:AdditionalPaidInCapitalMember2022-12-310000862668us-gaap:RetainedEarningsMember2022-12-3100008626682022-12-310000862668us-gaap:PreferredStockMember2023-01-012023-03-310000862668us-gaap:CommonStockMember2023-01-012023-03-310000862668us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000862668us-gaap:RetainedEarningsMember2023-01-012023-03-310000862668us-gaap:PreferredStockMember2023-03-310000862668us-gaap:CommonStockMember2023-03-310000862668us-gaap:AdditionalPaidInCapitalMember2023-03-310000862668us-gaap:RetainedEarningsMember2023-03-3100008626682023-03-310000862668us-gaap:ConvertiblePreferredStockMember2024-01-012024-03-310000862668us-gaap:ConvertiblePreferredStockMember2023-01-012023-03-310000862668us-gaap:ConvertiblePreferredStockMember2023-07-012024-03-310000862668us-gaap:ConvertiblePreferredStockMember2022-07-012023-03-310000862668us-gaap:StockOptionMember2024-01-012024-03-310000862668us-gaap:StockOptionMember2023-01-012023-03-310000862668us-gaap:StockOptionMember2023-07-012024-03-310000862668us-gaap:StockOptionMember2022-07-012023-03-3100008626682018-02-142018-02-1400008626682018-02-1400008626682022-07-012023-06-300000862668us-gaap:NotesPayableToBanksMember2018-06-290000862668us-gaap:NotesPayableToBanksMember2023-07-012024-03-310000862668esmc:TDBankMemberus-gaap:NotesPayableToBanksMember2023-03-290000862668esmc:TDBankMemberus-gaap:NotesPayableToBanksMember2023-03-292023-03-290000862668esmc:TDBankMemberus-gaap:NotesPayableToBanksMember2023-04-292023-04-290000862668esmc:TDBankMemberus-gaap:NotesPayableToBanksMember2024-03-310000862668us-gaap:SecuredDebtMember2024-03-310000862668us-gaap:SecuredDebtMember2023-03-312023-03-310000862668us-gaap:SecuredDebtMember2023-07-012024-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2023-07-012024-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012024-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-03-310000862668us-gaap:CustomerConcentrationRiskMemberesmc:CustomerTwoMemberus-gaap:SalesRevenueNetMember2023-01-012023-03-310000862668esmc:AccountsReceivableBenchmarkMember2023-07-012024-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-07-012024-03-310000862668us-gaap:CustomerConcentrationRiskMemberesmc:CustomerTwoMemberus-gaap:AccountsReceivableMember2023-07-012024-03-310000862668us-gaap:AccountsReceivableMember2023-07-012023-09-300000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-07-012023-09-300000862668us-gaap:AccountsReceivableMember2024-01-012024-03-310000862668us-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000862668esmc:SupplierTwoMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000862668us-gaap:AccountsReceivableMember2023-07-012024-03-310000862668us-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMemberus-gaap:SalesRevenueNetMember2023-07-012024-03-310000862668us-gaap:AccountsReceivableMember2023-01-012023-03-310000862668us-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMemberus-gaap:SalesRevenueNetMember2023-01-012023-03-310000862668esmc:SupplierTwoMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-03-310000862668us-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMemberus-gaap:SalesRevenueNetMember2022-07-012023-03-310000862668esmc:SupplierTwoMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-07-012023-03-310000862668esmc:AccountsPayableBenchmarkMemberus-gaap:SupplierConcentrationRiskMember2023-07-012024-03-310000862668esmc:AccountsPayableBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMember2023-07-012024-03-310000862668esmc:AccountsPayableBenchmarkMemberesmc:SupplierTwoMemberus-gaap:SupplierConcentrationRiskMember2023-07-012024-03-310000862668esmc:AccountsPayableBenchmarkMemberesmc:SupplierThreeMemberus-gaap:SupplierConcentrationRiskMember2023-07-012024-03-310000862668esmc:AccountsPayableBenchmarkMemberus-gaap:SupplierConcentrationRiskMember2023-07-012023-09-300000862668esmc:AccountsPayableBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMember2023-07-012023-12-310000862668esmc:AccountsPayableBenchmarkMemberesmc:SupplierTwoMemberus-gaap:SupplierConcentrationRiskMember2023-07-012023-12-310000862668us-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueNetMember2024-01-012024-03-310000862668us-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueNetMember2023-01-012023-03-310000862668us-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueNetMember2023-07-012024-03-310000862668us-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueNetMember2022-07-012023-03-310000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMemberus-gaap:SalesRevenueNetMember2023-01-012023-03-310000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMemberus-gaap:SalesRevenueNetMember2023-07-012024-03-310000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMemberus-gaap:SalesRevenueNetMember2022-07-012023-03-310000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-03-310000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012024-03-310000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-07-012023-03-310000862668us-gaap:GeographicConcentrationRiskMember2022-07-012023-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


 FORM 10-Q
QUARTERLY PERIOD PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934


For the Quarterly Period ended March 31, 2024
Commission File Number 0-20127


Escalon Medical Corp.
(Exact name of registrant as specified in its charter)

Pennsylvania 33-0272839
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
435 Devon Park Drive, Suite 824, Wayne, PA 19087
(Address of principal executive offices, including zip code)
(610) 688-6830
(Registrant’s telephone number, including area code)


N/A
Former name, former address and former fiscal year, if changed since last report
Securities registered pursuant to Section 12(b) of the Act: NONE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company. or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 


Large accelerated fileroAccelerated filero
Non-accelerated filer
x
Smaller reporting companyx
Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). o  Yes  x  No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 7,415,329 shares of common stock, $0.001 par value, outstanding as of May 13, 2024.




TABLE OF CONTENTS
  Page
PART I Financial Information
Item I.
Item 2.
Item 3.
Item 4.
PART II Other Information
Item 6.



1

PART I. FINANCIAL INFORMATION


Item I. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


2

ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

March 31,
2024		June 30,
2023
(Unaudited)
ASSETS
Current assets:
Cash $564,707 $889,674 
Restricted cash256,390 256,293 
Accounts receivable 1,491,827 1,807,599 
    Less: allowance for credit losses(132,624)(153,878)
Accounts receivable, net1,359,203 1,653,721 
Inventories, net1,804,929 1,587,989 
Other current assets166,600 249,790 
Total current assets4,151,829 4,637,467 
Property and equipment, net53,971 34,064 
Right-of-use assets276,089 503,647 
License and patent, net54,355 69,986 
Other long term assets62,787 62,787 
Total assets$4,599,031 $5,307,951 
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Current portion of note payable $33,262 $37,087 
Current portion of EIDL loan3,172 3,105 
Accounts payable1,118,057 1,205,510 
Accrued expenses589,877 651,978 
Related party accrued interest 112,389 112,389 
Current portion of operating lease liabilities
282,950 329,638 
Deferred revenue403,069 426,227 
Other short-term liabilities86,333 87,125 
Total current liabilities2,629,109 2,853,059 
Note payable, net of current portion135,483 159,511 
EIDL loan, net of current portion 143,289 146,435 
Operating lease liabilities, net of current portion15,974 214,103 
Total long-term liabilities294,746 520,049 
Total liabilities2,923,855 3,373,108 
Contingencies (Note 10)
Shareholders' equity:
Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized; 2,000,000 shares issued and outstanding (liquidation value of $961,173 and $922,331)645,000 645,000 
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding 7,415 7,415 
Additional paid-in capital69,702,043 69,702,043 
Accumulated deficit(68,679,282)(68,419,615)
Total shareholders’ equity1,675,176 1,934,843 
Total liabilities and shareholders’ equity$4,599,031 $5,307,951 
See notes to unaudited condensed consolidated financial statements.
3


ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Net revenues:
Products$2,567,387 $3,285,396 $8,101,834 $8,582,183 
Service plans128,114 148,918 407,904 462,436 
Revenues, net2,695,501 3,434,314 8,509,738 9,044,619 
Costs and expenses:
Cost of goods sold1,578,727 1,720,853 4,835,402 5,021,470 
Marketing, general and administrative1,117,534 938,161 3,401,902 3,108,177 
Research and development155,848 185,750 515,213 641,316 
Total costs and expenses
2,852,109 2,844,764 8,752,517 8,770,963 
(Loss) income from operations(156,608)589,550 (242,779)273,656 
Other expense
Interest expense(5,541)(4,315)(16,888)(15,188)
Income tax expense— — — — 
Net (loss) income(162,149)585,235 (259,667)258,468 
Undeclared dividends on preferred stocks12,830 13,006 38,842 38,735 
Net (loss) income applicable to common shareholders$(174,979)$572,229 $(298,509)$219,733 
Net (loss) income per share
Basic (loss) income per share$(0.02)$0.08 $(0.04)$0.03 
Diluted (loss) income per share$(0.02)$0.04 $(0.04)$0.02 
Weighted average shares—basic7,415,329 7,415,3297,415,329 7,415,329
Weighted average shares—diluted7,415,32913,478,9367,415,32913,478,936
See notes to unaudited condensed consolidated financial statements.
4


ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2024 AND 2023
(UNAUDITED)


 Series A Convertible Preferred StockCommon StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Shareholders’
Equity
 Shares AmountSharesAmount  
Balance at June 30, 20232,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,419,615)$1,934,843 
Net loss— — — — — (21,197)(21,197)
Balance at September 30, 20232,000,000 645,000 7,415,329 7,415 69,702,043 (68,440,812)1,913,646 
Net loss— — — — — (76,321)(76,321)
Balance at December 31, 20232,000,000 645,000 7,415,329 7,415 69,702,043 (68,517,133)1,837,325 
  Net loss— — — — — (162,149)(162,149)
Balance at March 31, 20242,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,679,282)$1,675,176 

 Series A Convertible Preferred StockCommon StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Shareholders’
Equity
 Shares AmountSharesAmount  
Balance at June 30, 20222,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,876,441)$1,478,017 
Net loss— — — — — (320,724)(320,724)
Balance at September 30, 20222,000,000 645,000 7,415,329 7,415 69,702,043 (69,197,165)1,157,293 
Net loss— — — — — (6,043)(6,043)
Balance at December 31, 20222,000,000 645,000 7,415,329 7,415 69,702,043 (69,203,208)1,151,250 
Net income— — — — — 585,235 585,235 
Balance at March 31, 20232,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,617,973)$1,736,485 


See notes to unaudited condensed consolidated financial statements.
5

ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
For the Nine Months Ended March 31,
20242023
Cash Flows from Operating Activities:
Net (loss) income$(259,667)$258,468 
Adjustments to reconcile net loss to net cash used in operating activities:
Change in allowance of doubtful accounts20,354 (93,400)
Depreciation and amortization
26,763 34,424 
Non cash lease expense
227,558 215,772 
Change in operating assets and liabilities:
Accounts receivable274,164 (107,573)
Inventories(216,940)(61,238)
Other current and non-current assets83,189 27,798 
Accounts payable (87,453)35,375 
   Accrued expenses
(62,101)(33,063)
Change in operating lease liability
(244,817)(226,404)
Deferred revenue(23,158)(36,985)
  Other short term and long term liabilities(792)(42,955)
Net cash used in operating activities(262,900)(29,781)
Cash Flows from Investing Activities:
  Purchase of equipment (31,038)(6,687)
 Purchase of patents— (7,155)
Net cash used in investing activities
(31,038)(13,842)
Cash Flows from Financing Activities:
Repayment of note payable(27,853)(3,165)
Repayment of EIDL loan(3,079)(2,686)
Net cash used in financing activities(30,932)(5,851)
Net decrease in cash, cash equivalents and restricted cash(324,870)(49,474)
Cash and restricted cash, beginning of period1,145,967 850,034 
Cash and restricted cash, end of period$821,097 $800,560 
Cash, cash equivalents and restricted cash consist of the following:
End of period
Cash $564,707 $544,320 
Restricted cash 256,390 256,240 
$821,097 $800,560 
6

Beginning of period
Cash $889,674 $593,869 
Restricted cash 256,293 256,165 
$1,145,967 $850,034 

Supplemental Schedule of Cash Flow Information:
Interest paid$16,985 $15,697 
See notes to unaudited condensed consolidated financial statements
7

Escalon Medical Corp. and Subsidiaries
Notes to Unaudited Condensed Consolidated Financial Statements

1. Organization and Basis of Presentation

          Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc.

    The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.
The accompanying unaudited condensed consolidated financial statements (“financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and have been consistently applied. Certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP, but which are not required for interim reporting purposes, have been omitted. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to present fairly the financial position as of March 31, 2024, and the results of operations and cash flows for the interim periods ended March 31, 2024 and 2023, have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended June 30, 2023 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on October 13, 2023. Operating results for the three months and nine months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the full year ending June 30, 2024.

    The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”

2. Going Concern

The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the continuous enhancement of the current products, development of new products; changes in domestic and foreign regulations; ability of manufacture successfully; competition from products manufactured and sold or being developed by other companies, the price of, and demand for, the Company’s products and its ability to raise capital to support its operations.

To date, the Company’s operations have not generated sufficient revenues to enable consistent profitability. Through March 31, 2024, the Company had incurred historical recurring losses from operations and incurred negative cash flows from operating activities. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for the next 12 months following the issuance of these unaudited condensed consolidated financial statements.

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company's continuance as a going concern is dependent on its future profitability and on the on-going support of its shareholders, affiliates and creditors. In order to mitigate the going concern issues, the Company is actively pursuing business partnerships, managing its continuing operations, and implementing cost-cutting measures. The Company may not be successful in any of these efforts.

3. Summary of Accounting Policies

Recently Issued Accounting Standards
8




In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (“ASC 326”), authoritative guidance amending how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The guidance requires the application of a current expected credit loss model, which is a new impairment model based on expected losses. The new guidance is effective for interim and annual reporting periods beginning after December 15, 2022. The adoption of the new guidance will not have a material impact on the Company's unaudited consolidated financial statements. The Company adopted the current expected credit loss model prospectively from fiscal year 2024, and assessed the allowance for expected credit losses to reflect the risk of loss, even when that risk is remote. The Company continues to use the aging matrix in conjunction with the historical information, current conditions, and reasonable and supportable forecasts. The Company groups most of the trade receivable by pools after adoption of the new standards while it analyzed the credit loss of the trade receivables one by one before adoption. The major difference is the estimate of the current expected credit loss for the receivable that are current on their payment. For the nine-month period ended March 31, 2024, the adoption of the new guidance did not have a material impact on the Company's unaudited consolidated financial statements. The Company will continue to assess the current expected credit loss. It may need to recognize a credit loss in the income statement earlier than under the legacy guidance at certain times when the expected credit loss is increased.
Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable and Allowance for Credit Losses

Accounts receivables are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company adopted the current expected credit loss model prospectively from fiscal year 2024, and assessed the allowance for expected credit losses to reflect the risk of loss, even when that risk is remote. The Company continues to use the aging matrix in conjunction with the historical information, current conditions and reasonable and supportable forecasts. The Company groups most of the trade receivable by pools after adoption of the new standards while it analyzed the credit loss of the trade receivables one by one before adoption. The major difference is the estimate of the current expected credit loss for the receivables that are current on their payment. With adoption of the new standards, the small credit loss rate applied to current receivables will be mostly offset by the lower expected credit rate applied to over 120 days past due when less than 100% of expected credit loss is applied. The historical credit loss rate is adjusted for current conditions and management's assessment for factors such as international relations, economic conditions, and special-term contracts etc. For the nine-month period ended March 31, 2024, the adoption of the new guidance did not have a material impact on the Company's unaudited consolidated financial statements. The Company will continue to assess the current expected credit loss. It may need to recognize a credit loss in the income statement earlier than under the legacy guidance at certain time when the expected credit loss is increased. The Company recorded an allowance for credit losses of approximately $132,624 and $153,878 as of March 31, 2024, and June 30, 2023, respectively.

The activity for the allowance for credit losses during the three-month and nine-month periods ended March 31, 2024, and the fiscal year ended June 30, 2023, is as follows:

9




 For the Three Months Ended March 31, For the Nine Months Ended March 31,
 2024202320242023
Balance, at the beginning of the period$133,524 $241,349 $153,878 $236,349 
Provision (Reversal)— (98,400)(20,354)(93,400)
Write-offs(900)— (900)— 
Balance, at the end of the period$132,624 $142,949 $132,624 $142,949 

Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on the age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely have impact on the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year.


Deferred Revenues

    The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the customer care plans for a 12-month period. The consideration received is recognized monthly over the service period. Revenue recorded that was included within prior period deferred revenue was $165,000 and $43,000, respectively for the three-month periods ended March 31, 2024 and 2023. Revenue recorded that was included within prior period deferred revenue was $440,000 and $300,000, respectively for nine month periods ended March 31, 2024, and 2023.

(in thousands)For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Beginning of Period$316 $259 $426 $332 
Additions284 185 560 425 
Revenue Recognized197 149 583 462 
End of Period$403 $295 $403 $295 

(Loss) earnings Per Share    
The Company utilizes the two-class method to compute net (loss) income per common share. These participating securities included the Company’s convertible preferred stock which accrues dividends payable. The two-class method requires (loss) earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.

Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had
10




all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.

Diluted net income per common share is computed under the two-class method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options. The Company analyzed the potential dilutive effect of any outstanding dilutive securities under the “if-converted” method and treasury-stock method when calculating diluted earnings per share, in which it is assumed that the outstanding participating securities convert into common stock at the beginning of the period or date of issuance, if later. The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. As of March 31, 2024 and 2023, the average market prices for the years then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive.
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Numerator:
  Numerator for basic loss per share:
 Net (loss) income$(162,149)$585,235 $(259,667)$258,468 
Undeclared dividends on preferred stock12,830 13,006 38,842 38,735 
Net (loss) income applicable to common shareholders$(174,979)$572,229 $(298,509)$219,733 
Numerator for diluted loss per share:
Diluted (loss) income$(162,149)$585,235 $(259,667)$258,468 
Undeclared dividends on preferred stock12,830 13,006 38,842 38,735 
Net (loss) income applicable to common shareholders$(174,979)$572,229 $(298,509)$219,733 
Denominator for basic (loss) earning per share
Denominator for basic (loss) earning per share - weighted average shares outstanding
7,415,329 7,415,329 7,415,329 7,415,329 
Weighted average preferred stock converted to common stock— 6,063,607 — 6,063,607 
 Denominator for diluted (loss) income assumed conversion7,415,329 13,478,936 7,415,329 13,478,936 
Net (loss) income per share:
Basic net (loss) income per share$(0.02)$0.08 $(0.04)$0.03 
Diluted net (loss) income per share$(0.02)$0.04 $(0.04)$0.02 
11





The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.

For the Three Months Ended March 31,For the Nine Months Ended March 31,
2024202320242023
Stock options157,000 157,000 157,000 157,000 
Convertible preferred stock6,407,820 — 6,407,820 — 
Total potential dilutive securities not included in loss per share6,564,820 157,000 6,564,820 157,000 

Income Taxes

    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of March 31, 2024 and June 30, 2023, the Company has recorded a full valuation allowance against its deferred tax assets.

    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. As of March 31, 2024, and June 30, 2023, no accrued interest or penalties were required to be included on the related tax liability line in the consolidated balance sheets.

4. Inventories

March 31,
June 30,
(in thousands)20242023
Inventories:
        Raw Material$1,027 $882 
        Work-In-Process388 86 
        Finished Goods650 881 
Total inventories$2,065 $1,849 
Allowance for obsolete inventory(260)(260)
Inventories, net$1,805 $1,588 

12




5. Related Party Transactions and Preferred Stock

    As of March 31, 2024, and 2023, the related party interest accrual of $112,389 related to the debt prior to the exchange, remained as an on demanded payable.
On February 14, 2018, the Company entered into a Debt Exchange Agreement (the “Exchange Agreement”) with Richard DePiano, Sr., (Mr. DePiano Sr.), the Company's former Chairman and DP Associates Inc. Profit-Sharing Plan of which Mr. DePiano Sr. is the sole owner and sole trustee (the “Holders”).  Pursuant to the terms of the Exchange Agreement, effective February 15, 2018, the Holders exchanged a total of $645,000 principal amount of debt related to the accounts receivable factoring program the Company owes the Holders for 2,000,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”).
    
    Each share of Preferred Stock entitles the Holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders.  As a result of this voting power, the Holders as of March 31, 2024 beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company’s shareholders.

    Subject to the terms and conditions of Preferred Stock, the holder of any share or shares of the Preferred Stock has the right, at its option at any time, to convert each such share of Preferred Stock (except that, upon any liquidation of the Company, the right of conversion will terminate at the close of business on the business day fixed for payment of the amounts distributable on the Preferred Stock) into 2.15 shares of Common Stock (the “Conversion Ratio”).  The Conversion Ratio is subject to standard provisions for adjustment in the event of a subdivision or combination of the Company’s Common Stock and upon any reorganization or reclassification of the capital stock of the Company. If the Holders were to convert their shares of Preferred Stock into Common Stock at the Conversion Ratio the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the then outstanding shares of Common Stock assuming such conversion.

    Each outstanding share of the Preferred Stock accrues dividends calculated cumulatively at the annual rate of $.0258 per share (such amount subject to equitable adjustment in the event of any stock dividend, stock split, combination, reclassification other similar event), payable upon the earlier of (i) a liquidation, dissolution or winding up of the Company or (ii) conversion of the Preferred Stock into Common Stock. Upon either of such events, all such accrued and unpaid dividends, whether or not earned or declared, to and until the date of such event, will become immediately due and payable and will be paid in full. The dividends payable to the holders of the Preferred Stock is payable in cash or, at the election of any such holder, in a number of additional shares of Common Stock equal to the amount of the dividend expressed in dollars divided by the then applicable Conversion Ratio, described above. As of March 31, 2024, and June 30, 2023, the cumulative dividends payable are $316,173 ($0.1581 per share) and $277,331 ($0.1387 per share), respectively.

    Mr. DePiano Sr. passed away on October 3, 2019, and left a will by which he appointed Richard J. DePiano, Jr., the Chief Executive Officer of the Company, as executor. Richard DePiano Jr. was elected to serve as Chairman of the Company's board. Mr. DePiano, Jr. qualified as executor and has control over the listed shares in his capacity as executor of Mr. DePiano Sr.'s estate.

6. TD Note Payable

    On June 29, 2018, the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.0% per annum. Interest on the unpaid principal balance of the note is calculated using a rate of 0.74 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.74% per annum based on a year of 360 days. The Company was required to put $250,000 in the TD bank savings account as collateral. The Loan is guaranteed by Mr. DePiano Jr.

TD bank elected to exercise the term note conversion option to convert the loan balance of $201,575 to a five-year term note effective March 29, 2023 the "Conversion Date"). The scheduled monthly principal and interest payments in the amount of $4,247 began on April 29, 2023. Commencing on the Conversion Date, the aggregate principal balance outstanding bears interest at a fixed per annum rate of 9.49% pursuant to the loan's terms and conditions.

The future note payable payments as of March 31, 2024 are as follows:

Year ending June 30,
TD Note Payment
13




2024 (remainder of FY 2024)
8,530 
2025
37,434 
2026
41,145 
202745,224 
202836,412 
Total
$168,745 

7. Long-term debt


Economic Injury Disaster Loan ("EIDL")

    EIDL is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to the Coronavirus (COVID-19) pandemic. EIDL proceeds can be used to cover a wide array of working capital and normal operating expenses, such as continuation to health care benefits, rent, utilities, and fixed debt payments. The Company received a $150,000 EIDL loan. The annual interest rate is 3.75%. The payment term is 30 years and the monthly payment of $731 started on July 1st, 2021. The EIDL loan is secured by the tangible and intangible personal property of the Company.

    The future annual principal amounts to be paid as of March 31, 2024 are as follows:
Year ending June 30,EIDL Payment
2024 (remainder of FY 2024)$782 
20253,202 
20263,324 
20273,451 
20283,582 
Thereafter132,120 
Total$146,461 

8. Concentration of Credit Risk

Credit Risk

Financial instruments, which potentially subject the Company to the concentration of credit risk, consist principally of cash and cash equivalents, restricted cash and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely addresses the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral.

Major Customer

    One customers accounted for 13% of net revenue during the three-month period ended March 31, 2024. One customer accounted for 11% of net revenue during the nine-month period ended March 31, 2024. No customer accounted for more than 10% during the three-month and nine-month periods ended March 31, 2023.

    As of March 31, 2024, the Company had two customers that represented 16% and 11% of the total accounts receivable balance. As of June 30, 2023, the Company had one customer that represented 24% of the total accounts receivable balance.

Major Supplier
14





    The Company's two largest suppliers accounted for 36% and 11% of total purchases for the three-month period ended March 31, 2024. The Company's one largest supplier accounted for 40% of total purchases for the nine-month period ended March 31, 2024. The Company's two largest suppliers accounted for 44% and 11% of total purchases for the three-month period ended March 31, 2023. The Company's two largest suppliers accounted for 44% and 10% of total purchases for the nine-month period ended March 31, 2023.

    As of March 31, 2024, the Company had three suppliers that represented 29%, 12%, and 11% of the total accounts payable balance. As of June 30, 2023, the Company had two suppliers that represented approximately 36% and 11% of the total accounts payable balance.

Disaggregated Revenue

    Domestic and international sales from operations are as follows:
(in thousands)For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Domestic$1,339 50 %$1,903 55 %$4,394 52 %$5,258 58 %
Foreign1,357 50 %1,531 45 %4,116 48 %3,787 42 %
Total$2,696 100 %$3,434 100 %$8,510 100 %$9,045 100 %

9. Leases

    The Company leases certain facilities and equipment under operating leases. Total lease expense, under ASC 842, was included in cost of goods sold and marketing, general and administrative costs in our unaudited condensed consolidated statements of operations for the three and nine months ended March 31, 2024, and 2023 as follows:

For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Operating lease costs:
Fixed$84,970 $85,324 $254,992 $256,084 
Total:$84,970 $85,324 $254,992 $256,084 

    Supplemental cash flow information was as follows:
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases$88,224 $86,350 $262,387 $256,883 
Total$88,224 $86,350 $262,387 $256,883 


    The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate)
under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheets as of March 31, 2024:
15




Operating
2024 (reminder of FY 2024)$88,514 
2025212,415 
20263,928 
20271,200 
20281,200 
Thereafter600 
Total lease payments307,857 
Less interest 8,933 
Present value of lease liabilities$298,924 

    Average lease terms and discount rates were as follows:
March 31,June 30,
20242023
Weighted-average remaining lease terms (years)
Operating leases
0.971.67
Weighted-average discount rate
Operating leases
5.72 %5.69 %

10. Contingencies
The Company, from time to time is involved in various legal proceedings and disputes that arise in the normal course of business. These matters have included intellectual property disputes, contract disputes, employment disputes and other matters. The Company does not believe that the resolution of any of these matters has had or is likely to have a material adverse impact on the Company’s business, financial condition or results of operations.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Statements

    Certain statements contained in, or incorporated by reference in, this report are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which provide current expectations or forecasts of future events. Such statements can be identified by the use of terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “possible,” “project,” “should,” “will,” and similar words or expressions. The Company's forward-looking statements include certain information relating to general business strategy, growth strategies, financial results, liquidity, the Company's ability to continue as a going concern, discontinued operations, research and development, product development, the introduction of new products, the potential markets and uses for the Company's products, the Company's ability to increase its sales campaign effectively, the Company's regulatory filings with the FDA, acquisitions, dispositions, the development of joint venture opportunities, intellectual property and patent protection and infringement, the loss of revenue due to the expiration or termination of certain agreements, the effect of competition on the structure of the markets in which the Company competes, increased legal, accounting and Sarbanes-Oxley compliance costs, information security, cybersecurity and data privacy risks, defending the Company in litigation matters and the Company's cost saving initiatives. The reader must carefully consider forward-looking statements and understand that such statements involve a variety of risks and uncertainties, known and unknown, and may be affected by assumptions that fail to materialize as anticipated, including risks related to the COVID-19 pandemic, inflation, the ability to continue as a going concern including the ability to raise capital, manage operations and pursue business partnerships and cost-cutting measures, and the other risks described in the Company's Form 10-K for the fiscal year ended June 30, 2023. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. It is not possible to foresee or identify all factors affecting the Company's forward-looking statements, and the reader therefore should not consider the list of such factors contained in its periodic report on Form 10-K for the year ended June 30, 2023 and this Form 10-Q quarterly report to be an exhaustive statement of all risks, uncertainties or potentially inaccurate assumptions.
16





Executive Overview—nine-month periods ended March 31, 2024, and 2023
The following highlights are discussed in further detail within this Form 10-Q. The reader is encouraged to read this Form 10-Q in its entirety to gain a more complete understanding of factors impacting Company performance and financial condition.

•Consolidated net revenue decreased approximately $535,000 or 5.9%, to $8,510,000 during the nine months ended March 31, 2024, as compared to the same period of last fiscal year. The decrease in net revenue is mainly attributed to a decrease in sales of Sonomed's ultrasound products of $467,000 during the nine months ended March 31, 2024.

•Consolidated cost of goods sold totaled approximately $4,836,000, or 56.8%, of total revenue for the nine months ended March 31, 2024, as compared to $5,021,000, or 55.5%, of total revenue of the same period of last fiscal year. The increase of 1.3% in cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix and geographic differences during the nine months ended March 31, 2024.

•Consolidated marketing, general and administrative expenses increased $294,000, or 9.5%, to $3,402,000 for the nine months ended March 31, 2024, as compared to the same period of last fiscal year. The increase in marketing, general and administrative expenses is mainly due to the recovery of bad debts of $113,000 during the prior year, tax expenses, and increase travel expense during the three months ended March 31, 2024.

•Consolidated research and development expenses decreased $126,000, or 19.7%, to $515,000 for the nine months ended March 31, 2024, as compared to the same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The decrease in research and development expenses is mainly due to decreased image management consulting expense during the nine months ended March 31, 2024.
Company Overview

    The following discussion should be read in conjunction with the interim unaudited condensed consolidated financial statements and the notes thereto, which are set forth in Item 1 of this report.

    The Company operates in the healthcare market specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the FDA. The FDA requires extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing. The Company's Internet address is www.escalonmed.com. Under the trade name of Sonomed-Escalon the Company develops, manufactures and markets ultrasound systems used for diagnosis or biometric applications in ophthalmology, develops, manufactures and distributes ophthalmic surgical products under the Trek Medical Products name, and manufactures and markets image management systems.
Critical Accounting Estimates
The preparation of unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact amounts reported therein. On a regular basis, we evaluate these estimates. These estimates are based on management’s historical industry experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

For a description of the accounting policies that, in management’s opinion, involve the most significant application of judgment or involve complex estimation and which could, if different judgment or estimates were made, materially affect our reported financial position, results of operations, or cash flows, see the notes to consolidated financial statements included in the Form 10-K for the year ended June 30, 2023.

During the nine months ended March 31, 2024, the Company adopted ASU 2016-13, Financial Instruments - Credit Losses, however there were no significant impact and no changes in our significant accounting estimates to our unaudited condensed consolidated financial statements.
17





Results of Operations
Three Months and Nine Months Ended March 31, 2024, and 2023
The following table shows consolidated net revenue, as well as identifying trends in revenues for the three months and nine months ended March 31, 2024, and 2023. Table amounts are in thousands:
 For the Three Months Ended March 31, For the Nine Months Ended March 31,
 20242023% Change20242023% Change
Net Revenue:
Products$2,568 $3,285 (21.8)%$8,102 $8,582 (5.6)%
Service plans128 149 (14.1)%408 463 (11.9)%
Total$2,696 $3,434 (21.5)%$8,510 $9,045 (5.9)%
    
Consolidated net revenue decreased approximately $738,000 or 21.5%, to $2,696,000 during the three months ended March 31, 2024, as compared to the same period of last fiscal year. The decrease in net revenue is mainly attributed to a decrease in sales of Sonomed's ultrasound products of $701,000 during the three months ended March 31, 2024.

Consolidated net revenue decreased approximately $535,000 or 5.9%, to $8,510,000 during the nine months ended March 31, 2024, as compared to the same period of last fiscal year. The decrease in net revenue is mainly attributed to a decrease in sales of Sonomed's ultrasound products of $467,000 during the nine months ended March 31, 2024.

The following table presents the domestic and foreign sales for the three months and nine months ended March 31, 2024, and 2022. The table amounts are in thousands:
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Domestic$1,339 49.7 %$1,903 55.4 %$4,394 51.6 %$5,258 58.1 %
Foreign1,357 50.3 %1,531 44.6 %4,116 48.4 %3,787 41.9 %
Total$2,696 100.0 %$3,434 100.0 %$8,510 100.0 %$9,045 100.0 %

The following table presents consolidated cost of goods sold and as a percentage of revenues for the three months and nine months ended March 31, 2024, and 2022. Table amounts are in thousands:

 
 For the Three Months Ended March 31, For the Nine Months Ended March 31,
 2024%2023%2024%2023%
Cost of Goods Sold:
$1,579 58.6 %$1,721 50.1 %4,836 56.8 %5,021 55.5 %
Total$1,579 58.6 %$1,721 50.1 %4,836 56.8 %5,021 55.5 %


Consolidated cost of goods sold totaled approximately $1,579,000, or 58.6%, of total revenue for the three months ended March 31, 2024, as compared to $1,721,000, or 50.1%, of total revenue of the same period of last fiscal year. The increase of 8.5% in the cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix and geographic differences during the three months ended March 31, 2024.

Consolidated cost of goods sold totaled approximately $4,836,000, or 56.8%, of total revenue for the nine months ended March 31, 2024, as compared to $5,021,000, or 55.5%, of total revenue of the same period of last fiscal year. The increase of 1.3% in the cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix and geographic differences during the nine months ended March 31, 2024.

18




    The following table presents consolidated marketing, general and administrative expenses for three months and nine months ended March 31, 2024, and 2023. Table amounts are in thousands:
 
 For the Three Months Ended March 31, For the Nine Months Ended March 31,
 20242023% Change 20242023% Change 
Marketing, General and Administrative:
$1,118 $938 19.2 %$3,402 $3,108 9.5 %
Total$1,118 $938 19.2 %$3,402 $3,108 9.5 %

Consolidated marketing, general and administrative expenses increased $180,000, or 19.2%, to $1,118,000 for the three months ended March 31, 2024, as compared to the same period of last fiscal year. The increase in marketing, general and administrative expenses is mainly due to the recovery of bad debts of $113,000 during the prior year, tax expenses, and increase travel expense during the three months ended March 31, 2024.

Consolidated marketing, general and administrative expenses increased $294,000, or 9.5%, to $3,402,000 for the nine months ended March 31, 2024, as compared to the same period of last fiscal year. The increase in marketing, general and administrative expenses is mainly due to he recovery of bad debts of $113,000 during the prior year, temporary hiring costs, increased network expenses and travel expenses during the nine months ended March 31, 2024.

The following table presents consolidated research and development expenses for the three months and nine months ended March 31, 2024, and 2023.
Table amounts are in thousands:
For the Three Months Ended March 31, For the Nine Months Ended March 31,
 20242023% Change  20242023% Change
Research and Development:
$156 $186 (16.1)%515 $641 (19.7)%
Total$156 $186 (16.1)%$515 $641 (19.7)%

Consolidated research and development expenses decreased $30,000, or 16.1%, to $156,000 for the three months ended March 31, 2024, as compared to the same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The decrease in research and development expenses is mainly due to decreased image management consulting expenses offset by the increased current year's new consulting services designing the housing and mechanical inner parts of probes during the three months ended March 31, 2024.
Consolidated research and development expenses decreased $126,000, or 19.7%, to $515,000 for the nine months ended March 31, 2024, as compared to the same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The decrease in research and development expenses is mainly due to decreased image management consulting expense during the nine months ended March 31, 2024.

Russia-Ukraine War

In February 2022, Russia invaded Ukraine. As military activity proceeds and sanctions, export controls and other measures are imposed by many countries against Russia, Belarus and specific areas of Ukraine, the war is increasingly affecting the global economy and financial markets, as well as exacerbating ongoing economic challenges, including rising inflation and global supply-chain disruption.

Israel-Hamas war

19




In October 2023, Hamas terrorists attacked Israel, and then Israel declared war and decimated the Gaza Strip. The Israel-Hamas war and conflicts could affect economic activity via lower trade with the Middle East, disruption of supply chain and collection of trade receivables in the region.

The Company has operations or activities in countries and regions outside the United States. As a result, its global operations are affected by economic, political, and other conditions in the foreign countries in which it does business as well as U.S. laws regulating international trade, although the Company has not yet assessed that these wars have had a material effect on its financial position or results of operations.    

Liquidity and Capital Resources

Our total cash on hand as of March 31, 2024 was approximately $565,000 of cash on hand and restricted cash of approximately $256,000 compared to approximately $890,000 of cash on hand and restricted cash of $256,000 as of June 30, 2023.

Because the Company's operations have not historically generated sufficient revenues to enable profitability, we will continue to monitor costs and expenses closely and may need to raise additional capital or take other actions to fund operations.

The Company expects to continue to fund operations from cash on hand and through capital raising sources if possible and available, which may be dilutive to existing stockholders, through revenues from the licensing of the Company's products, or through strategic alliances. Additionally, we may seek to sell additional equity or debt securities through one or more discrete transactions, or enter a strategic alliance arrangement, but can provide no assurances that any such financing or strategic alliance arrangement will be available on acceptable terms, or at all. Moreover, the incurrence of indebtedness in connection with a debt financing would result in increased fixed obligations and could contain covenants that would restrict our operations.

As of March 31, 2024, we had an accumulated deficit of approximately $68.7 million, historically incurred recurring losses from operations and negative cash flows from operating activities. These factors raise substantial doubt regarding our ability to continue as a going concern, and our ability to generate cash to meet our cash requirements for the following twelve months as of the date of this form 10-Q.
    
The following table presents overall liquidity and capital resources as of March 31, 2024, and June 30, 2023. Table amounts are in thousands:
 
March 31,June 30,
 20242023
Current Ratio:
Current assets$4,152$4,637
Less: Current liabilities2,6292,853
Working capital$1,523$1,784
Current ratio1.58 to 11.63 to 1
Debt to Total Capital Ratio:
Note payable, lease liabilities, and EIDL loan$614$890
Total debt 614890
Total equity 1,6751,935
Total capital $2,290$2,825
Total debt to total capital 26.8%31.5%
20




Working Capital Position
Working capital decreased approximately $261,000 as of March 31, 2024, and the current ratio decreased to 1.58 to 1 from 1.63 to 1 when compared to June 30, 2023.
Debt to total capital ratio was 26.8% and 31.5%  as of March 31, 2024, and June 30, 2023, respectively. The decrease of debt to total capital ratio is mainly due to lease payments.
Cash Flow Used in Operating Activities
During the nine months ended March 31, 2024, the Company used approximately $263,000 of cash in operating activities as compared to cash of approximately $30,000 used in operating activities during the nine months ended March 31, 2024.
    For the nine months ended March 31, 2024, its cash used in operations is due to an increase in inventory of $217,000, a decrease in accounts payable of $87,000, a decrease in lease liability of $245,000, and a decrease in deferred revenue of $23,000, offset by a decrease in accounts receivable of $274,000 and a decrease in current assets of $83,000. The remaining offsetting items for cash provided by operations is comprised of less significant items.
     For the nine months ended March 31, 2023, its cash used in operations is due to operating income of $258,000, an increase in accounts payable of $35,000, and a decrease in other current and non-current assets of $28,000, offset by an increase in accounts receivable of approximately $108,000, an increase of inventory of $61,000, a repayment of employer tax deferral of $43,000, and a decrease of other deferred revenue of $37,000 and a decrease in accrued expense of $33,000. The remaining offsetting items for cash provided by operations is comprised of less significant items
Cash Flows used in Investing Activities
Cash flows used in investing activities for the nine months ended March 31, 2024 was due to purchase of fixed assets of $31,000. Cash flows used in investing activities for the nine-month period ended March 31, 2023 was due to the addition to the patent of $7,000 and addition to the fixed assets of $7,000.
Cash Flows Used in Financing Activities
For the nine months ended March 31, 2024 the cash used in financing activities was due to loan payments of $28,000 and repayment of EIDL loan of $3,000. For the nine months ended March 31, 2023 the cash used in financing activities was due to an auto loan payment of $3,000 and repayment of EIDL loan of $3,000.
Item 3.    Quantitative and Qualitative Disclosures About Market Risk

None.

Item 4. Controls and Procedures

(A)    Evaluation of Disclosure Controls and Procedures

The Company's management, with the participation of the Company's Chief Executive Officer and Principal Financial and Accounting Officer, have established disclosure controls and procedures to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the officers who certify the Company's financial reports and to other members of senior management and the Board of Directors.

Based on their evaluation of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2024, the Chief Executive Officer and Principal Financial and Accounting Officer of the Company have concluded that such disclosure controls and procedures are not effective to ensure that the information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its Chief Executive Officer and Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosure. We identified a material weakness in internal control related to the proper design and implementation of controls over our estimates relating to the valuation of inventory and allowance for doubtful accounts, specifically over the precision of management’s review during the year end June 30, 2023.


21




(B)    Internal Control over Financial Reporting

There have not been any changes in the Company's internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act), during the third quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Part II. OTHER INFORMATION
Item 5. Other Information

None.
Item 6.    Exhibits


Signatures
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Escalon Medical Corp.
(Registrant)
Date: May 14, 2024By:/s/ Richard J. DePiano, Jr.
Richard J. DePiano, Jr.
Chief Executive Officer
Date: May 14, 2024By:/s/ Mark Wallace
Mark Wallace
Chief Operating Officer and Principal Accounting & Financial Officer

22

Exhibit 31.1
Certification of Principal Executive Officer
I, Richard J. DePiano, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Escalon Medical Corp.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/    Richard J. DePiano Jr.
Richard J. DePiano Jr.
Chief Executive Officer
Date: May 14, 2024



Exhibit 31.2


Certification of Principal Financial Officer
I, Mark Wallace, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Escalon Medical Corp.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/    Mark Wallace
Mark Wallace
Date: May 14, 2024



Exhibit 32.1

Certification pursuant to 18 U.S.C. Section 1350,
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
I, Richard J. DePiano Jr., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Quarterly Report of Escalon Medical Corp. on Form 10Q for the quarterly period ended March 31, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 14, 2024
 
/s/    Richard J. DePiano Jr.
Richard J. DePiano Jr.
Chief Executive Officer




Exhibit 32.2

Certification pursuant to 18 U.S.C. Section 1350,
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, Mark Wallace, Chief Operating Officer and Principal Accounting & Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Quarterly Report of Escalon Medical Corp. on Form 10-Q for the quarterly period ended March 31, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 14, 2024
 
/s/    Mark Wallace
Mark Wallace
Chief Operating Officer and Principal Accounting & Financial Officer



v3.24.1.1.u2
Cover - shares
 9 Months Ended
Mar. 31, 2024
May 13, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Entity Registrant Name Escalon Medical Corp.  
Entity Incorporation, State or Country Code PA  
Entity Tax Identification Number 33-0272839  
Entity Address, Address Line One 435 Devon Park Drive  
Entity Address, City or Town Wayne  
Document Transition Report false  
Entity File Number 000-20127  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 19087  
City Area Code (610)  
Local Phone Number 688-6830  
Entity Emerging Growth Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   7,415,329
Title of 12(b) Security common stock, $0.001 par value  
Entity Central Index Key 0000862668  
Current Fiscal Year End Date --06-30  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
v3.24.1.1.u2
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2024
Jun. 30, 2023
Current assets:    
Cash and cash equivalents $ 564,707 $ 889,674
Restricted Cash, Current 256,390 256,293
Accounts Receivable 1,491,827 1,807,599
Accounts Receivable, Allowance for Credit Loss (132,624) (153,878)
Accounts Receivable, after Allowance for Credit Loss 1,359,203 1,653,721
Inventory, net 1,804,929 1,587,989
Other current assets 166,600 249,790
Total current assets 4,151,829 4,637,467
Property and equipment, net 53,971 34,064
Operating Lease, Right-of-Use Asset 276,089 503,647
Finite-Lived Intangible Assets, Net 54,355 69,986
Deposits Assets, Noncurrent 62,787 62,787
Total assets 4,599,031 5,307,951
Current liabilities:    
Other Notes Payable, Current 33,262 37,087
Secured Debt, Current 3,172 3,105
Accounts payable 1,118,057 1,205,510
Accrued expenses 589,877 651,978
Interest Payable, Current 112,389 112,389
Operating Lease, Liability, Current 282,950 329,638
Deferred Revenue 403,069 426,227
Other short-term liabilities 86,333 87,125
Total current liabilities 2,629,109 2,853,059
Other Notes Payable, Noncurrent 135,483 159,511
Operating Lease, Liability, Noncurrent 15,974 214,103
Total long-term liabilities 294,746 520,049
Total liabilities 2,923,855 3,373,108
Shareholders equity:    
Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized;2,000,000 issued and outstanding 645,000 645,000
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding 7,415 7,415
Additional paid-in capital 69,702,043 69,702,043
Accumulated deficit (68,679,282) (68,419,615)
Total shareholders' equity 1,675,176 1,934,843
Total liabilities and shareholders' equity 4,599,031 5,307,951
Secured Debt [Member]    
Current liabilities:    
Secured Long-term Debt, Noncurrent $ 143,289 $ 146,435
v3.24.1.1.u2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2024
Jun. 30, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 2,000,000 2,000,000
Preferred Stock, Shares Issued 2,000,000 2,000,000
Common stock, par value   $ 0.001
Common stock, shares authorized 35,000,000 35,000,000
Common stock, shares issued 7,415,329 7,415,329
Common stock, shares outstanding 7,415,329 7,415,329
v3.24.1.1.u2
Condensed Consolidated Statements Of Operations - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Revenue from External Customer [Line Items]        
Revenues $ 2,695,501 $ 3,434,314 $ 8,509,738 $ 9,044,619
Costs and expenses:        
Cost of Goods and Services Sold 1,578,727 1,720,853 4,835,402 5,021,470
Marketing, general and administrative 1,117,534 938,161 3,401,902 3,108,177
Research and development 155,848 185,750 515,213 641,316
Total costs and expenses 2,852,109 2,844,764 8,752,517 8,770,963
(Loss) income from operations (156,608) 589,550 (242,779) 273,656
Other (expense) income:        
Other Nonoperating Income (Expense) 0 0 0 0
Interest expense (5,541) (4,315) (16,888) (15,188)
Net (loss) income (162,149) 585,235 (259,667) 258,468
Preferred Stock Dividends, Income Statement Impact 12,830 13,006 38,842 38,735
Net Income (Loss) Available to Common Stockholders, Basic $ (174,979) $ 572,229 $ (298,509) $ 219,733
Net income (loss) per share        
Earnings (Loss) Per Share, Basic $ (0.02) $ 0.08 $ (0.04) $ 0.03
Earnings (Loss) Per Share, Diluted $ (0.02) $ 0.04 $ (0.04) $ 0.02
Weighted average shares - basic 7,415,329 7,415,329 7,415,329 7,415,329
Weighted Average Number of Shares Outstanding, Diluted 7,415,329 13,478,936 7,415,329 13,478,936
Product [Member]        
Revenue from External Customer [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax $ 2,567,387 $ 3,285,396 $ 8,101,834 $ 8,582,183
Service [Member]        
Revenue from External Customer [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax $ 128,114 $ 148,918 $ 407,904 $ 462,436
v3.24.1.1.u2
Condensed Consolidated Statements Of Shareholders' Equity - USD ($)
Total
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Balance at Jun. 30, 2022 $ 1,478,017     $ 69,702,043 $ (68,876,441)
Net (loss) income (320,724) $ 0 $ 0 0 (320,724)
Balance at Sep. 30, 2022 1,157,293     69,702,043 (69,197,165)
Balance at Jun. 30, 2022 1,478,017     69,702,043 (68,876,441)
Net (loss) income 258,468        
Balance at Mar. 31, 2023 1,736,485     69,702,043 (68,617,973)
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Balance at Sep. 30, 2022 1,157,293     69,702,043 (69,197,165)
Net (loss) income (6,043) $ 0 $ 0 0 (6,043)
Balance at Dec. 31, 2022 1,151,250     69,702,043 (69,203,208)
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Net (loss) income 585,235 $ 0 $ 0 0 585,235
Balance at Mar. 31, 2023 1,736,485     69,702,043 (68,617,973)
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued 645,000   $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding $ 7,415 $ 7,415      
Common Stock, Shares, Outstanding 7,415,329 7,415,329      
Balance at Jun. 30, 2023 $ 1,934,843     69,702,043 (68,419,615)
Net (loss) income (21,197) $ 0 $ 0 0 (21,197)
Balance at Sep. 30, 2023 1,913,646     69,702,043 (68,440,812)
Balance at Jun. 30, 2023 1,934,843     69,702,043 (68,419,615)
Net (loss) income (259,667)        
Balance at Mar. 31, 2024 1,675,176     69,702,043 (68,679,282)
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Balance at Sep. 30, 2023 1,913,646     69,702,043 (68,440,812)
Net (loss) income (76,321) $ 0 $ 0 0 (76,321)
Balance at Dec. 31, 2023 1,837,325     69,702,043 (68,517,133)
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Net (loss) income (162,149) $ 0 $ 0 0 (162,149)
Balance at Mar. 31, 2024 $ 1,675,176     $ 69,702,043 $ (68,679,282)
Preferred Stock, Shares Outstanding     2,000,000    
Convertible Preferred Stock, Shares Issued upon Conversion 2.15        
Preferred Stock, Value, Issued $ 645,000   $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding $ 7,415 $ 7,415      
Common Stock, Shares, Outstanding 7,415,329 7,415,329      
v3.24.1.1.u2
Condensed Consolidated Statements Of Cash Flows - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Cash Flows from Operating Activities:        
Net (loss) income $ (162,149) $ 585,235 $ (259,667) $ 258,468
Accounts Receivable, Credit Loss Expense (Reversal) 0 (98,400) 20,354 (93,400)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization     26,763 34,424
Change in operating assets and liabilities:        
Increaser(Decrease) in Accounts Receivable     274,164 (107,573)
Increase (Decrease) in Inventories     (216,940) (61,238)
Increase (Decrease) in Other Operating Assets     83,189 27,798
Increase (Decrease) in Deferred Revenue     (23,158) (36,985)
Increase (Decrease) in Accounts Payable     (87,453) 35,375
Increase (Decrease) in Accrued Liabilities     (62,101) (33,063)
Increase (Decrease) in Other Operating Liabilities     (244,817) (226,404)
Other Operating Activities, Cash Flow Statement     227,558 215,772
Increase (Decrease) in Other Deferred Liability     (792) (42,955)
Net Cash Provided by (Used in) Operating Activities     (262,900) (29,781)
Payments to Acquire Property, Plant, and Equipment     (31,038) (6,687)
Cash Flows from Investing Activities:        
Payments to Acquire Intangible Assets     0 (7,155)
Net Cash Provided by (Used in) Investing Activities     (31,038) (13,842)
Net Cash provided by (used in) Financing Activities:        
Repayments of Notes Payable     (27,853) (3,165)
Repayment of EIDL loan     (3,079) (2,686)
Net Cash Provided by (Used in) Financing Activities     (30,932) (5,851)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect     (324,870) (49,474)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning of Period     1,145,967 850,034
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, End of Period 821,097 800,560 821,097 800,560
Cash and cash equivalents 564,707 544,320 564,707 544,320
Restricted Cash 256,390 256,240 256,390 256,240
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $ 821,097 $ 800,560 821,097 800,560
Supplemental Schedule of Cash Flow Information:        
Interest Paid, Excluding Capitalized Interest, Operating Activities     $ 16,985 $ 15,697
v3.24.1.1.u2
Organization and Description of Business
 9 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Description of Business and Business Conditions Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc.
    The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.
The accompanying unaudited condensed consolidated financial statements (“financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and have been consistently applied. Certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP, but which are not required for interim reporting purposes, have been omitted. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to present fairly the financial position as of March 31, 2024, and the results of operations and cash flows for the interim periods ended March 31, 2024 and 2023, have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended June 30, 2023 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on October 13, 2023. Operating results for the three months and nine months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the full year ending June 30, 2024.

    The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”
v3.24.1.1.u2
Going concern (Notes)
 9 Months Ended
Mar. 31, 2024
Going concern [Abstract]  
Liquidity Disclosure [Policy Text Block] . Going Concern
The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the continuous enhancement of the current products, development of new products; changes in domestic and foreign regulations; ability of manufacture successfully; competition from products manufactured and sold or being developed by other companies, the price of, and demand for, the Company’s products and its ability to raise capital to support its operations.

To date, the Company’s operations have not generated sufficient revenues to enable consistent profitability. Through March 31, 2024, the Company had incurred historical recurring losses from operations and incurred negative cash flows from operating activities. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for the next 12 months following the issuance of these unaudited condensed consolidated financial statements.

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company's continuance as a going concern is dependent on its future profitability and on the on-going support of its shareholders, affiliates and creditors. In order to mitigate the going concern issues, the Company is actively pursuing business partnerships, managing its continuing operations, and implementing cost-cutting measures. The Company may not be successful in any of these efforts.
v3.24.1.1.u2
Inventory (Notes)
 9 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Inventory Disclosure [Text Block] Inventories
March 31,
June 30,
(in thousands)20242023
Inventories:
        Raw Material$1,027 $882 
        Work-In-Process388 86 
        Finished Goods650 881 
Total inventories$2,065 $1,849 
Allowance for obsolete inventory(260)(260)
Inventories, net$1,805 $1,588 
v3.24.1.1.u2
Related Party Transactions
 9 Months Ended
Mar. 31, 2024
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions and Preferred Stock
    As of March 31, 2024, and 2023, the related party interest accrual of $112,389 related to the debt prior to the exchange, remained as an on demanded payable.
On February 14, 2018, the Company entered into a Debt Exchange Agreement (the “Exchange Agreement”) with Richard DePiano, Sr., (Mr. DePiano Sr.), the Company's former Chairman and DP Associates Inc. Profit-Sharing Plan of which Mr. DePiano Sr. is the sole owner and sole trustee (the “Holders”).  Pursuant to the terms of the Exchange Agreement, effective February 15, 2018, the Holders exchanged a total of $645,000 principal amount of debt related to the accounts receivable factoring program the Company owes the Holders for 2,000,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”).
    
    Each share of Preferred Stock entitles the Holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders.  As a result of this voting power, the Holders as of March 31, 2024 beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company’s shareholders.

    Subject to the terms and conditions of Preferred Stock, the holder of any share or shares of the Preferred Stock has the right, at its option at any time, to convert each such share of Preferred Stock (except that, upon any liquidation of the Company, the right of conversion will terminate at the close of business on the business day fixed for payment of the amounts distributable on the Preferred Stock) into 2.15 shares of Common Stock (the “Conversion Ratio”).  The Conversion Ratio is subject to standard provisions for adjustment in the event of a subdivision or combination of the Company’s Common Stock and upon any reorganization or reclassification of the capital stock of the Company. If the Holders were to convert their shares of Preferred Stock into Common Stock at the Conversion Ratio the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the then outstanding shares of Common Stock assuming such conversion.

    Each outstanding share of the Preferred Stock accrues dividends calculated cumulatively at the annual rate of $.0258 per share (such amount subject to equitable adjustment in the event of any stock dividend, stock split, combination, reclassification other similar event), payable upon the earlier of (i) a liquidation, dissolution or winding up of the Company or (ii) conversion of the Preferred Stock into Common Stock. Upon either of such events, all such accrued and unpaid dividends, whether or not earned or declared, to and until the date of such event, will become immediately due and payable and will be paid in full. The dividends payable to the holders of the Preferred Stock is payable in cash or, at the election of any such holder, in a number of additional shares of Common Stock equal to the amount of the dividend expressed in dollars divided by the then applicable Conversion Ratio, described above. As of March 31, 2024, and June 30, 2023, the cumulative dividends payable are $316,173 ($0.1581 per share) and $277,331 ($0.1387 per share), respectively.

    Mr. DePiano Sr. passed away on October 3, 2019, and left a will by which he appointed Richard J. DePiano, Jr., the Chief Executive Officer of the Company, as executor. Richard DePiano Jr. was elected to serve as Chairman of the Company's board. Mr. DePiano, Jr. qualified as executor and has control over the listed shares in his capacity as executor of Mr. DePiano Sr.'s estate.
v3.24.1.1.u2
Line of Credit
 9 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Line of Credit On June 29, 2018, the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.0% per annum. Interest on the unpaid principal balance of the note is calculated using a rate of 0.74 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.74% per annum based on a year of 360 days. The Company was required to put $250,000 in the TD bank savings account as collateral. The Loan is guaranteed by Mr. DePiano Jr.
TD bank elected to exercise the term note conversion option to convert the loan balance of $201,575 to a five-year term note effective March 29, 2023 the "Conversion Date"). The scheduled monthly principal and interest payments in the amount of $4,247 began on April 29, 2023. Commencing on the Conversion Date, the aggregate principal balance outstanding bears interest at a fixed per annum rate of 9.49% pursuant to the loan's terms and conditions.

The future note payable payments as of March 31, 2024 are as follows:

Year ending June 30,
TD Note Payment
2024 (remainder of FY 2024)
8,530 
2025
37,434 
2026
41,145 
202745,224 
202836,412 
Total
$168,745 
v3.24.1.1.u2
Long term debt (Notes)
 9 Months Ended
Mar. 31, 2024
Debt Instrument [Line Items]  
Long-term Debt [Text Block]
Economic Injury Disaster Loan ("EIDL")

    EIDL is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to the Coronavirus (COVID-19) pandemic. EIDL proceeds can be used to cover a wide array of working capital and normal operating expenses, such as continuation to health care benefits, rent, utilities, and fixed debt payments. The Company received a $150,000 EIDL loan. The annual interest rate is 3.75%. The payment term is 30 years and the monthly payment of $731 started on July 1st, 2021. The EIDL loan is secured by the tangible and intangible personal property of the Company.

    The future annual principal amounts to be paid as of March 31, 2024 are as follows:
Year ending June 30,EIDL Payment
2024 (remainder of FY 2024)$782 
20253,202 
20263,324 
20273,451 
20283,582 
Thereafter132,120 
Total$146,461 
v3.24.1.1.u2
Concentration of credit risk (Notes)
 3 Months Ended
Sep. 30, 2023
Concentration Risk [Line Items]  
Concentration Risk Disclosure [Text Block]
Credit Risk

Financial instruments, which potentially subject the Company to the concentration of credit risk, consist principally of cash and cash equivalents, restricted cash and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely addresses the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral.

Major Customer

    One customers accounted for 13% of net revenue during the three-month period ended March 31, 2024. One customer accounted for 11% of net revenue during the nine-month period ended March 31, 2024. No customer accounted for more than 10% during the three-month and nine-month periods ended March 31, 2023.

    As of March 31, 2024, the Company had two customers that represented 16% and 11% of the total accounts receivable balance. As of June 30, 2023, the Company had one customer that represented 24% of the total accounts receivable balance.

Major Supplier
    The Company's two largest suppliers accounted for 36% and 11% of total purchases for the three-month period ended March 31, 2024. The Company's one largest supplier accounted for 40% of total purchases for the nine-month period ended March 31, 2024. The Company's two largest suppliers accounted for 44% and 11% of total purchases for the three-month period ended March 31, 2023. The Company's two largest suppliers accounted for 44% and 10% of total purchases for the nine-month period ended March 31, 2023.

    As of March 31, 2024, the Company had three suppliers that represented 29%, 12%, and 11% of the total accounts payable balance. As of June 30, 2023, the Company had two suppliers that represented approximately 36% and 11% of the total accounts payable balance.

Disaggregated Revenue

    Domestic and international sales from operations are as follows:
(in thousands)For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Domestic$1,339 50 %$1,903 55 %$4,394 52 %$5,258 58 %
Foreign1,357 50 %1,531 45 %4,116 48 %3,787 42 %
Total$2,696 100 %$3,434 100 %$8,510 100 %$9,045 100 %
v3.24.1.1.u2
Leases (Notes)
 9 Months Ended
Mar. 31, 2024
Lessee Disclosure [Abstract]  
Lease Leases
    The Company leases certain facilities and equipment under operating leases. Total lease expense, under ASC 842, was included in cost of goods sold and marketing, general and administrative costs in our unaudited condensed consolidated statements of operations for the three and nine months ended March 31, 2024, and 2023 as follows:

For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Operating lease costs:
Fixed$84,970 $85,324 $254,992 $256,084 
Total:$84,970 $85,324 $254,992 $256,084 

    Supplemental cash flow information was as follows:
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases$88,224 $86,350 $262,387 $256,883 
Total$88,224 $86,350 $262,387 $256,883 


    The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate)
under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheets as of March 31, 2024:
Operating
2024 (reminder of FY 2024)$88,514 
2025212,415 
20263,928 
20271,200 
20281,200 
Thereafter600 
Total lease payments307,857 
Less interest 8,933 
Present value of lease liabilities$298,924 

    Average lease terms and discount rates were as follows:
March 31,June 30,
20242023
Weighted-average remaining lease terms (years)
Operating leases
0.971.67
Weighted-average discount rate
Operating leases
5.72 %5.69 %
v3.24.1.1.u2
Commitment and Contingencies
 9 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Contingencies
The Company, from time to time is involved in various legal proceedings and disputes that arise in the normal course of business. These matters have included intellectual property disputes, contract disputes, employment disputes and other matters. The Company does not believe that the resolution of any of these matters has had or is likely to have a material adverse impact on the Company’s business, financial condition or results of operations.
v3.24.1.1.u2
Significant Accounting Policies (Policies)
 9 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
New Accounting Pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (“ASC 326”), authoritative guidance amending how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The guidance requires the application of a current expected credit loss model, which is a new impairment model based on expected losses. The new guidance is effective for interim and annual reporting periods beginning after December 15, 2022. The adoption of the new guidance will not have a material impact on the Company's unaudited consolidated financial statements. The Company adopted the current expected credit loss model prospectively from fiscal year 2024, and assessed the allowance for expected credit losses to reflect the risk of loss, even when that risk is remote. The Company continues to use the aging matrix in conjunction with the historical information, current conditions, and reasonable and supportable forecasts. The Company groups most of the trade receivable by pools after adoption of the new standards while it analyzed the credit loss of the trade receivables one by one before adoption. The major difference is the estimate of the current expected credit loss for the receivable that are current on their payment. For the nine-month period ended March 31, 2024, the adoption of the new guidance did not have a material impact on the Company's unaudited consolidated financial statements. The Company will continue to assess the current expected credit loss. It may need to recognize a credit loss in the income statement earlier than under the legacy guidance at certain times when the expected credit loss is increased.
Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable
Accounts receivables are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company adopted the current expected credit loss model prospectively from fiscal year 2024, and assessed the allowance for expected credit losses to reflect the risk of loss, even when that risk is remote. The Company continues to use the aging matrix in conjunction with the historical information, current conditions and reasonable and supportable forecasts. The Company groups most of the trade receivable by pools after adoption of the new standards while it analyzed the credit loss of the trade receivables one by one before adoption. The major difference is the estimate of the current expected credit loss for the receivables that are current on their payment. With adoption of the new standards, the small credit loss rate applied to current receivables will be mostly offset by the lower expected credit rate applied to over 120 days past due when less than 100% of expected credit loss is applied. The historical credit loss rate is adjusted for current conditions and management's assessment for factors such as international relations, economic conditions, and special-term contracts etc. For the nine-month period ended March 31, 2024, the adoption of the new guidance did not have a material impact on the Company's unaudited consolidated financial statements. The Company will continue to assess the current expected credit loss. It may need to recognize a credit loss in the income statement earlier than under the legacy guidance at certain time when the expected credit loss is increased. The Company recorded an allowance for credit losses of approximately $132,624 and $153,878 as of March 31, 2024, and June 30, 2023, respectively.

The activity for the allowance for credit losses during the three-month and nine-month periods ended March 31, 2024, and the fiscal year ended June 30, 2023, is as follows:
 For the Three Months Ended March 31, For the Nine Months Ended March 31,
 2024202320242023
Balance, at the beginning of the period$133,524 $241,349 $153,878 $236,349 
Provision (Reversal)— (98,400)(20,354)(93,400)
Write-offs(900)— (900)— 
Balance, at the end of the period$132,624 $142,949 $132,624 $142,949 
Inventory Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on the age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely have impact on the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year.
Net Income (loss) Per Share The Company utilizes the two-class method to compute net (loss) income per common share. These participating securities included the Company’s convertible preferred stock which accrues dividends payable. The two-class method requires (loss) earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.
Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had
all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.

Diluted net income per common share is computed under the two-class method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options. The Company analyzed the potential dilutive effect of any outstanding dilutive securities under the “if-converted” method and treasury-stock method when calculating diluted earnings per share, in which it is assumed that the outstanding participating securities convert into common stock at the beginning of the period or date of issuance, if later. The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. As of March 31, 2024 and 2023, the average market prices for the years then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive.
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Numerator:
  Numerator for basic loss per share:
 Net (loss) income$(162,149)$585,235 $(259,667)$258,468 
Undeclared dividends on preferred stock12,830 13,006 38,842 38,735 
Net (loss) income applicable to common shareholders$(174,979)$572,229 $(298,509)$219,733 
Numerator for diluted loss per share:
Diluted (loss) income$(162,149)$585,235 $(259,667)$258,468 
Undeclared dividends on preferred stock12,830 13,006 38,842 38,735 
Net (loss) income applicable to common shareholders$(174,979)$572,229 $(298,509)$219,733 
Denominator for basic (loss) earning per share
Denominator for basic (loss) earning per share - weighted average shares outstanding
7,415,329 7,415,329 7,415,329 7,415,329 
Weighted average preferred stock converted to common stock— 6,063,607 — 6,063,607 
 Denominator for diluted (loss) income assumed conversion7,415,329 13,478,936 7,415,329 13,478,936 
Net (loss) income per share:
Basic net (loss) income per share$(0.02)$0.08 $(0.04)$0.03 
Diluted net (loss) income per share$(0.02)$0.04 $(0.04)$0.02 
The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.

For the Three Months Ended March 31,For the Nine Months Ended March 31,
2024202320242023
Stock options157,000 157,000 157,000 157,000 
Convertible preferred stock6,407,820 — 6,407,820 — 
Total potential dilutive securities not included in loss per share6,564,820 157,000 6,564,820 157,000 
Income Taxes
Income Taxes

    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of March 31, 2024 and June 30, 2023, the Company has recorded a full valuation allowance against its deferred tax assets.

    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. As of March 31, 2024, and June 30, 2023, no accrued interest or penalties were required to be included on the related tax liability line in the consolidated balance sheets.
v3.24.1.1.u2
Significant Accounting Policies (Tables)
 9 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]
(in thousands)For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Beginning of Period$316 $259 $426 $332 
Additions284 185 560 425 
Revenue Recognized197 149 583 462 
End of Period$403 $295 $403 $295 
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Numerator:
  Numerator for basic loss per share:
 Net (loss) income$(162,149)$585,235 $(259,667)$258,468 
Undeclared dividends on preferred stock12,830 13,006 38,842 38,735 
Net (loss) income applicable to common shareholders$(174,979)$572,229 $(298,509)$219,733 
Numerator for diluted loss per share:
Diluted (loss) income$(162,149)$585,235 $(259,667)$258,468 
Undeclared dividends on preferred stock12,830 13,006 38,842 38,735 
Net (loss) income applicable to common shareholders$(174,979)$572,229 $(298,509)$219,733 
Denominator for basic (loss) earning per share
Denominator for basic (loss) earning per share - weighted average shares outstanding
7,415,329 7,415,329 7,415,329 7,415,329 
Weighted average preferred stock converted to common stock— 6,063,607 — 6,063,607 
 Denominator for diluted (loss) income assumed conversion7,415,329 13,478,936 7,415,329 13,478,936 
Net (loss) income per share:
Basic net (loss) income per share$(0.02)$0.08 $(0.04)$0.03 
Diluted net (loss) income per share$(0.02)$0.04 $(0.04)$0.02 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.

For the Three Months Ended March 31,For the Nine Months Ended March 31,
2024202320242023
Stock options157,000 157,000 157,000 157,000 
Convertible preferred stock6,407,820 — 6,407,820 — 
Total potential dilutive securities not included in loss per share6,564,820 157,000 6,564,820 157,000 
Accounts Receivable, Allowance for Credit Loss
 For the Three Months Ended March 31, For the Nine Months Ended March 31,
 2024202320242023
Balance, at the beginning of the period$133,524 $241,349 $153,878 $236,349 
Provision (Reversal)— (98,400)(20,354)(93,400)
Write-offs(900)— (900)— 
Balance, at the end of the period$132,624 $142,949 $132,624 $142,949 
v3.24.1.1.u2
Inventory (Tables)
 9 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current [Table Text Block]
March 31,
June 30,
(in thousands)20242023
Inventories:
        Raw Material$1,027 $882 
        Work-In-Process388 86 
        Finished Goods650 881 
Total inventories$2,065 $1,849 
Allowance for obsolete inventory(260)(260)
Inventories, net$1,805 $1,588 
v3.24.1.1.u2
Line of Credit (Tables)
 9 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Maturities of Line of Credit
Year ending June 30,
TD Note Payment
2024 (remainder of FY 2024)
8,530 
2025
37,434 
2026
41,145 
202745,224 
202836,412 
Total
$168,745 
Year ending June 30,EIDL Payment
2024 (remainder of FY 2024)$782 
20253,202 
20263,324 
20273,451 
20283,582 
Thereafter132,120 
Total$146,461 
v3.24.1.1.u2
Long term debt (Tables)
 9 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Maturities of Long-term Debt
Year ending June 30,
TD Note Payment
2024 (remainder of FY 2024)
8,530 
2025
37,434 
2026
41,145 
202745,224 
202836,412 
Total
$168,745 
Year ending June 30,EIDL Payment
2024 (remainder of FY 2024)$782 
20253,202 
20263,324 
20273,451 
20283,582 
Thereafter132,120 
Total$146,461 
Contractual Obligation, Fiscal Year Maturity The future annual principal amounts to be paid as of March 31, 2024 are as follows:
Year ending June 30,EIDL Payment
2024 (remainder of FY 2024)$782 
20253,202 
20263,324 
20273,451 
20283,582 
Thereafter132,120 
Total$146,461 
v3.24.1.1.u2
Concentration of credit risk (Tables)
 9 Months Ended
Mar. 31, 2024
Concentration of credit risks [Abstract]  
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Domestic and international sales from operations are as follows:
(in thousands)For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Domestic$1,339 50 %$1,903 55 %$4,394 52 %$5,258 58 %
Foreign1,357 50 %1,531 45 %4,116 48 %3,787 42 %
Total$2,696 100 %$3,434 100 %$8,510 100 %$9,045 100 %
v3.24.1.1.u2
Leases (Tables) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Lessee Disclosure [Abstract]        
Lease, Cost [Table Text Block]    
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Operating lease costs:
Fixed$84,970 $85,324 $254,992 $256,084 
Total:$84,970 $85,324 $254,992 $256,084 
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases$88,224 $86,350 $262,387 $256,883 
Total$88,224 $86,350 $262,387 $256,883 
March 31,June 30,
20242023
Weighted-average remaining lease terms (years)
Operating leases
0.971.67
Weighted-average discount rate
Operating leases
5.72 %5.69 %
  
Short-term Lease Payments $ 88,224 $ 86,350 $ 262,387 $ 256,883
Lessee, Operating Lease, Liability, Maturity    
Operating
2024 (reminder of FY 2024)$88,514 
2025212,415 
20263,928 
20271,200 
20281,200 
Thereafter600 
Total lease payments307,857 
Less interest 8,933 
Present value of lease liabilities$298,924 
  
v3.24.1.1.u2
Going concern (Details) - USD ($)
Mar. 31, 2024
Jun. 30, 2023
Going concern [Abstract]    
Retained Earnings (Accumulated Deficit) $ (68,679,282) $ (68,419,615)
v3.24.1.1.u2
Significant Accounting Policies (Inventory) (Details) - USD ($)
Mar. 31, 2024
Jun. 30, 2023
schedule of inventory [Abstract]    
Inventory, net $ 1,804,929 $ 1,587,989
v3.24.1.1.u2
Significant Accounting Policies (Accounts Receivable) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Sep. 30, 2023
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Jun. 30, 2023
Dec. 31, 2022
Jun. 30, 2022
Accounting Policies [Abstract]                  
Accounts Receivable, Allowance for Credit Loss $ 132,624   $ 142,949 $ 132,624 $ 142,949 $ 133,524 $ 153,878 $ 241,349 $ 236,349
Accounts Receivable, Credit Loss Expense (Reversal) 0 $ 93,400 98,400 (20,354) $ 93,400        
Accounts Receivable, Allowance for Credit Loss, Writeoff $ (900) $ 0 $ 0 $ (900)          
v3.24.1.1.u2
Significant Accounting Policies (Net Income (loss) Per Share) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Sep. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                
Net (loss) income $ (162,149) $ (76,321) $ (21,197) $ 585,235 $ (6,043) $ (320,724) $ (259,667) $ 258,468
Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic $ (174,979)     $ 572,229     $ (298,509) $ 219,733
Basic Weighted average shares outstanding 7,415,329     7,415,329     7,415,329 7,415,329
Weighted Average Number of Shares Outstanding, Diluted 7,415,329     13,478,936     7,415,329 13,478,936
v3.24.1.1.u2
Significant Accounting Policies Earning per share details (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Sep. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                
Net (loss) income $ (162,149) $ (76,321) $ (21,197) $ 585,235 $ (6,043) $ (320,724) $ (259,667) $ 258,468
Net Income (Loss) Available to Common Stockholders, Diluted $ (174,979)     $ 572,229     $ (298,509) $ 219,733
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6,564,820     157,000     6,564,820 157,000
Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic $ (174,979)     $ 572,229     $ (298,509) $ 219,733
Convertible Preferred Dividends, Net of Tax             $ 38,842 $ 38,735
Weighted average shares - basic 7,415,329     7,415,329     7,415,329 7,415,329
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock             0 6,063,607
Weighted average shares - diluted 7,415,329     13,478,936     7,415,329 13,478,936
Earnings (Loss) Per Share, Basic $ (0.02)     $ 0.08     $ (0.04) $ 0.03
Earnings (Loss) Per Share, Diluted $ (0.02)     $ 0.04     $ (0.04) $ 0.02
Preferred Stock Dividends, Income Statement Impact $ 12,830     $ 13,006     $ 38,842 $ 38,735
Net Income (Loss) Available to Common Stockholders, Basic $ (174,979)     $ 572,229     $ (298,509) $ 219,733
Convertible Preferred Stock [Member]                
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 157,000     157,000     157,000 157,000
Equity Option [Member]                
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6,407,820     0     6,407,820 0
v3.24.1.1.u2
Significant Accounting Policies deferred revenue (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Revenue Recognition and Deferred Revenue [Abstract]        
Deferred Revenue $ 316,000 $ 259,000 $ 426,227 $ 332,000
Deferred Revenue, Additions 284,000 185,000 560,000 425,000
Deferred Revenue, Revenue Recognized 197,000 149,000 583,000 462,000
Deferred Revenue 403,069 295,000 403,069 295,000
Recognized revenue that was included within prior period deferred revenue $ 165,000 $ 43,000 $ 440,000 $ 300,000
v3.24.1.1.u2
Significant Accounting Policies New accounting pronouncements recently adopted (Details) - USD ($)
Mar. 31, 2024
Jun. 30, 2023
New accounting pronouncements recently adopted [Abstract]    
Operating Lease, Right-of-Use Asset $ 276,089 $ 503,647
v3.24.1.1.u2
Inventory (Details) - USD ($)
Mar. 31, 2024
Jun. 30, 2023
Inventory Disclosure [Abstract]    
Inventory, net $ 1,804,929 $ 1,587,989
Inventory, Raw Materials, Gross 1,027,000 882,000
Inventory, Work in Process, Gross 388,000 86,000
Inventory, Finished Goods, Gross 650,000 881,000
Inventory Valuation Reserves (260,000) (260,000)
Inventory, Gross $ 2,065,000 $ 1,849,000
v3.24.1.1.u2
Related Party Transactions (Details)
 9 Months Ended 12 Months Ended
Feb. 14, 2018
USD ($)
$ / shares
shares
Mar. 31, 2024
USD ($)
vote
$ / shares
shares
Jun. 30, 2023
USD ($)
$ / shares
shares
Related Party Transactions [Abstract]      
Related Party Transaction, Amounts of Transaction | $ $ 645,000    
Preferred Stock, Shares Issued | shares 2,000,000 2,000,000 2,000,000
Preferred stock, number of votes per share | vote   13  
Common Stock, Voting Rights   77.81  
Convertible Preferred Stock, Shares Issued upon Conversion | shares   2.15  
Common Stock, Conversion Basis   4,300,000  
Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion   36.70%  
Dividends Payable, Amount Per Share | $ / shares $ (0.0258) $ (0.1581) $ (0.1387)
Dividends Payable, Date to be Paid | $   $ 316,173 $ 277,331
v3.24.1.1.u2
Line of Credit (Details) - Note Payable - USD ($)
 9 Months Ended
Apr. 29, 2023
Mar. 29, 2023
Mar. 31, 2024
Jun. 29, 2018
Line of Credit Facility [Line Items]        
Notes Payable to Bank       $ 250,000
Debt Instrument, Interest Rate, Stated Percentage       5.00%
Debt Instrument, Basis Spread on Variable Rate     74.00%  
Debt Instrument, Interest Rate During Period     5.74%  
TD Bank        
Line of Credit Facility [Line Items]        
Debt Instrument, Interest Rate, Stated Percentage   9.49%    
Note payable, face amount   $ 201,575    
Debt instrument, term   5 years    
Monthly principal and interest payments $ 4,247      
v3.24.1.1.u2
Line of Credit - Maturity Schedule (Details) - TD Bank - Note Payable
Mar. 31, 2024
USD ($)
Line of Credit Facility [Line Items]  
2025 $ 8,530
2026 37,434
2027 41,145
2028 45,224
2028 36,412
Total $ 168,745
v3.24.1.1.u2
Long term debt (Details) - USD ($)
 9 Months Ended
Mar. 31, 2023
Mar. 29, 2023
Mar. 31, 2024
Secured Debt [Member]      
Debt Instrument [Line Items]      
Debt instrument, term 30 years    
Debt Instrument, Periodic Payment     $ 731
Long-term Debt     $ 150,000
Secured Debt [Member]      
Debt Instrument [Line Items]      
Long-term Debt, Weighted Average Interest Rate, at Point in Time     3.75%
2024 (remainder of FY 2024)     $ 782
2025     3,202
2026     3,324
2027     3,451
2028     3,582
Thereafter     132,120
Long-term Debt     146,461
Note Payable | TD Bank      
Debt Instrument [Line Items]      
Debt instrument, term   5 years  
2025     8,530
2026     37,434
2027     41,145
2028     45,224
Long-term Debt     $ 168,745
v3.24.1.1.u2
Concentration of credit risk (Details) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended
Mar. 31, 2024
Sep. 30, 2023
Mar. 31, 2023
Dec. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Concentration Risk [Line Items]            
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]         Domestic and international sales from operations are as follows:
(in thousands)For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Domestic$1,339 50 %$1,903 55 %$4,394 52 %$5,258 58 %
Foreign1,357 50 %1,531 45 %4,116 48 %3,787 42 %
Total$2,696 100 %$3,434 100 %$8,510 100 %$9,045 100 %
  
Revenues $ 2,695,501   $ 3,434,314   $ 8,509,738 $ 9,044,619
Customer Concentration Risk [Member] | Customer One [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Customer One   No   One  
Geographic Concentration Risk [Member]            
Concentration Risk [Line Items]            
Revenues           $ 9,045,000
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 13.00%   10.00%   11.00%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer two            
Concentration Risk [Line Items]            
Concentration Risk, Percentage          
Revenue Benchmark [Member] | Geographic Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 100.00%   100.00%   100.00% 100.00%
Revenues $ 2,696,000   $ 3,434,000   $ 8,510,000 $ 9,045,000
Accounts Payable Benchmark [Member] | Supplier Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Supplier   two     three  
Accounts Receivable Benchmark [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Customer         two  
Accounts Receivable            
Concentration Risk [Line Items]            
Concentration Risk, Customer two one two   one  
Accounts Receivable | Customer Concentration Risk [Member] | Customer One [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage   24.00%     16.00%  
Accounts Receivable | Customer Concentration Risk [Member] | Customer two            
Concentration Risk [Line Items]            
Concentration Risk, Percentage         11.00%  
Domestic [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 50.00%   55.00%   52.00% 58.00%
Revenues $ 1,339,000   $ 1,903,000   $ 4,394,000 $ 5,258,000
International [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 50.00%   45.00%   48.00% 42.00%
Revenues $ 1,357,000   $ 1,531,000   $ 4,116,000 $ 3,787,000
Supplier one [Member] | Revenue Benchmark [Member] | Supplier Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 36.00%   44.00%   40.00% 44.00%
Supplier one [Member] | Accounts Payable Benchmark [Member] | Supplier Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage       36.00% 29.00%  
Supplier two [Member] | Revenue Benchmark [Member] | Supplier Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 11.00%   11.00%     10.00%
Supplier two [Member] | Accounts Payable Benchmark [Member] | Supplier Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage       11.00% 12.00%  
Supplier Three | Accounts Payable Benchmark [Member] | Supplier Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage         11.00%  
v3.24.1.1.u2
Leases (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Jun. 30, 2023
Lessee Disclosure [Abstract]          
Operating Lease, Cost $ 84,970 $ 85,324 $ 254,992 $ 256,084  
Short-term Lease Payments 88,224 $ 86,350 262,387 $ 256,883  
2024 (reminder of FY 2024) 88,514   88,514    
2025 212,415   212,415    
2026 3,928   3,928    
2027 1,200   1,200    
2028 1,200   1,200    
Thereafter 600   600    
Total lease payments 307,857   307,857    
Interest portion in the future lease payments 8,933   8,933    
Net present value of new lease future payments $ 298,924   $ 298,924    
Operating Lease, Weighted Average Remaining Lease Term 11 months 19 days   11 months 19 days   1 year 8 months 1 day
Operating Lease, Weighted Average Discount Rate, Percent 5.72%   5.72%   5.69%
v3.24.1.1.u2
Label Element Value
Restricted Cash us-gaap_RestrictedCash $ 256,293
Restricted Cash us-gaap_RestrictedCash $ 256,165
Escalon Medical (QB) (USOTC:ESMC)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Escalon Medical (QB) Charts.
Escalon Medical (QB) (USOTC:ESMC)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Escalon Medical (QB) Charts.